- GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide.
- It has been subjected to an unwarranted selloff due to a slower than expected commercial launch despite the fact that this is likely a short-term impact due to COVID-19.
- With management making an effort to make physicians more aware of Oxbryta and to increase coverage of Oxbryta, the long-term growth trajectory of Oxbryta should not be affected.
- Currently, GBT trades at an incredibly conservative multiple of just $2bil EV despite being a market leader in a sector estimated to be worth at least $28bil.
For further details see:
Global Blood Therapeutics: 40% Discount On A Billion-Dollar Drug